SCHEMBL6311516

SCHEMBL6311516

Cc1ccc2cc(Nc3ccnc(Cl)n3)ccc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.49
TERT O14746 3/20 0.47
DOT1L Q8TEK3 2/20 0.47
PIK3CA P42336 1/20 0.44
CYP1A2 P05177 1/20 0.42
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
ABCB1 P08183 1/20 0.41
ABCC1 P33527 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
KDM4E B2RXH2 2/20 0.41
POLB P06746 2/20 0.41
LMNA P02545 1/20 0.41
CASP6 P55212 1/20 0.41
IGF1R P08069 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3A P46098 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3388994 0.80 IGF1R (0.55) NPC1RAB9AABCB1ABCC1ABCG2
SCHEMBL6312915 0.78 IGF1R (0.52) TERTDOT1LNPC1RAB9AABCB1
SCHEMBL13485393 0.78 KDM4E (0.44) TERTDOT1LCYP1A2NPC1RAB9A
Hydrochloric Acid SCHEMBL16014168 0.78 KDM1A (0.49) KDM1ATERTDOT1LPIK3CACYP1A2
SCHEMBL659167 0.77 MEN1 (0.49) NPC1RAB9AKDM4EPOLBMEN1
SCHEMBL6979830 0.76 ALDH1A1 (0.50) TERTDOT1LRAB9APOLBIGF1R
SCHEMBL3455225 0.76 ALDH1A1 (0.47) TERTDOT1LPIK3CACYP1A2POLB
SCHEMBL5394104 0.76 EPHB4 (0.45) CYP1A2NPC1RAB9ALMNAMEN1
SCHEMBL4006514 0.75 KDM1A (0.46) KDM1APIK3CACYP1A2NPC1RAB9A
SCHEMBL16012326 0.75 PIK3CA (0.49) KDM1ATERTDOT1LPIK3CACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939874-B2 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. (US) 2005-09-06 US disclosed
EP-1427421-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS Amgen Inc. (US) 2004-06-16 EP disclosed
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. 2004-04-01 US disclosed
WO-2003018021-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS AMGEN INC. (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use DPYD, TYMP, TPMT KDM1A 3420/4885TERT 762/4885DOT1L 3571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.